{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-063987","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.090859+00:00","generated_at":"2026-05-22T12:14:40.792418+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cogent Biosciences Q1 net loss $72M; cash $245.7M; SUMMIT readout in July","bullets":["Net loss $72.0M vs $58.3M YoY; R&D spend $63.0M (+20% YoY) driven by ongoing trials.","Cash & securities $245.7M, funded into late 2026; raised $24.3M via ATM in Q1.","Top-line SUMMIT results in non-AdvSM due July 2025; APEX AdvSM in H2, PEAK GIST by year-end.","Bezuclastinib OLE data showed 65% mean TSS improvement at 48 weeks; 88% achieved ≥50% reduction.","Early-stage pipeline (KRAS, PI3Kα, FGFR2/3, ErbB2) preclinical data presented at AACR."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-063987","json":"https://secwatch.observer/filing/0000950170-25-063987.json","markdown":"https://secwatch.observer/filing/0000950170-25-063987.md","text":"https://secwatch.observer/filing/0000950170-25-063987.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000095017025063987/0000950170-25-063987-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000095017025063987/cogt-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T12:14:40.792418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}